

This Provisional PDF corresponds to the article as it appeared upon acceptance. Copyedited and fully formatted PDF and full text (HTML) versions will be made available soon.

## **Porphyromonas gingivalis and the pathogenesis of rheumatoid arthritis: analysis of various compartments including the synovial tissue**

*Arthritis Research & Therapy* 2013, **15**:R66 doi:10.1186/ar4243

Michele C Totaro (micheleciro@gmail.com)  
Paola Cattani (pcattani@rm.unicatt.it)  
Francesco Ria (fria@rm.unicatt.it)  
Barbara Tolusso (ba.tolusso@gmail.com)  
Elisa Gremese (elisa.gremese@rm.unicatt.it)  
Anna L Fedele (annalaura.fedele@edu.rm.unicatt.it)  
Sara D'Onghia (saronzola@katamail.com)  
Simona Marchetti (simona.marchetti@rm.unicatt.it)  
Gabriele Di Sante (gabriele.disante@hotmail.it)  
Silvia Canestri (silvia.canestri@yahoo.it)  
Gianfranco Ferraccioli (gf.ferraccioli@rm.unicatt.it)

**ISSN** 1478-6354

**Article type** Research article

**Submission date** 29 July 2012

**Acceptance date** 11 April 2013

**Publication date** 18 June 2013

**Article URL** <http://arthritis-research.com/content/15/3/R66>

This peer-reviewed article can be downloaded, printed and distributed freely for any purposes (see copyright notice below).

Articles in *Arthritis Research & Therapy* are listed in PubMed and archived at PubMed Central.

For information about publishing your research in *Arthritis Research & Therapy* go to

<http://arthritis-research.com/authors/instructions/>

© 2013 Totaro *et al.*

This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

***Porphyromonas gingivalis* and the pathogenesis of rheumatoid arthritis: analysis of various compartments including the synovial tissue**

Michele Ciro Totaro<sup>1</sup>, Paola Cattani<sup>2</sup>, Francesco Ria<sup>3</sup>, Barbara Tolusso<sup>1</sup>, Elisa Gremese<sup>1</sup>, Anna Laura Fedele<sup>1</sup>, Sara D'Onghia<sup>2</sup>, Simona Marchetti<sup>2</sup>, Gabriele Di Sante<sup>3</sup>, Silvia Canestri<sup>1</sup> and Gianfranco Ferraccioli<sup>1\*</sup>

<sup>1</sup>Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Via G. Moscati 31, Rome, 00168, Italy. <sup>2</sup>Laboratory of Clinical analyses, Association Columbus, Catholic University of the Sacred Heart, Via G. Moscati 31, Rome, 00168, Italy. <sup>3</sup>Institute of General Pathology, Catholic University of the Sacred Heart, Largo F. Vito 1, Rome, 00168, Italy

\*Corresponding author: Gianfranco Ferraccioli, [gf.ferraccioli@rm.unicatt.it](mailto:gf.ferraccioli@rm.unicatt.it)

## **Abstract**

**Introduction:** We evaluated the presence of *Porphyromonas gingivalis* (Pg) DNA in the synovial tissue through synovial biopsy and in other compartments of RA patients in comparison with patients affected by other arthritides. Possible links with clinical, immunologic and genetic features were assessed.

**Methods:** Peripheral blood (PB), sub-gingival dental plaque, synovial fluid (SF) and synovial tissue samples were collected from 69 patients with active knee arthritis (32 with RA and 37 with other arthritides, of which 14 with undifferentiated peripheral inflammatory arthritis - UPIA). Demographic, clinical, laboratory and immunological data were recorded. The presence of Pg DNA was evaluated through PCR. The HLA-DR haplotype was assessed for 45 patients with RA and UPIA.

**Results:** No differences arose in the positivity for Pg DNA in the sub-gingival plaque, PB and SF samples between RA and the cohort of other arthritides. Full PB samples showed a higher positivity for Pg DNA than plasma samples (11.8% vs. 1.5%,  $p=0.04$ ). Patients with RA showed a higher positivity for Pg DNA in the synovial tissue compared to controls (33.3% vs. 5.9%,  $p<0.01$ ). UPIA and RA patients carrying the HLA DRB1\*04 allele showed a higher positivity for Pg DNA in the synovial tissue compared to patients negative for the allele (57.1% vs. 16.7%,  $p=0.04$ ). RA patients positive for Pg DNA in the sub-gingival plaque had a lower disease duration and a higher peripheral blood leucocytes and neutrophils count. The presence of Pg DNA did not influence disease activity, disease disability or positivity for autoantibodies.

**Conclusions:** The presence of Pg DNA in the synovial tissue of RA patients suggests a pathogenic role of the bacterium. The higher positivity of Pg DNA in full peripheral blood

and synovial tissue samples compared to plasma and synovial fluid suggests a possible intracellular localization of Pg, in particular in patients positive for HLA-DR4.

## Introduction

Rheumatoid arthritis (RA) is a chronic systemic inflammatory autoimmune disease. Reasons for the loss of immunologic tolerance against auto-antigens are partially unknown. Genetic factors are thought to be responsible only for 50-60% of the RA heritability [1]. HLA alleles DRB1\*01 and \*04, the main genetic risk factor for RA, are primarily involved in the antigen presentation process [2]. Environmental factors like smoking, together with genetic factors, play roles in the development of RA, possibly through the loss of tolerance against citrullinated peptides [3]. Citrullination is a process involved in the pathogenesis of RA, and the conversion of arginine to citrulline allows for a high affinity antigen interaction with the HLA-DRB1\*04 allele [4]. Bacteria may play a role as well, activating the immune system against auto-antigens, through the mechanism of the so-called “molecular mimicry” [5]. Following the model of reactive arthritis [6], the research of bacterial antigens in the joint compartment of RA patients lent to few positive results, mainly in the synovial tissue compared to the synovial fluid [7], thus supporting the idea of a prevalence of intracellular bacteria. Alive bacteria have never been isolated, to date, in the joint compartment of RA patients. The role of these bacterial structures is unknown: they can be bystanders related to the recruitment of inflammatory cells, or they may play a specific part in the etiology of the disease.

Recently, *Porphyromonas gingivalis* (Pg), a periodontal anaerobic intracellular pathogen [8], has been associated to RA and the pathogenesis of the disease [9, 10], mainly for the ability of the bacterium to citrullinate host and bacterial peptides [11], unique in the prokaryotic world. Periodontitis is known to be epidemiologically associated to RA [12], and its pathogenesis, including the genetic background, has many points in common with RA [13]. As a support for the possible role of Pg in the pathogenesis of RA, antibodies against Pg

have been found to be associated with RA and with anti-citrullinated protein antibodies (ACPA) [14]. Moreover, the DNA of Pg has been detected in the synovial fluid and plasma samples from patients with RA [15], and the coexistence of RA and periodontitis increased the probability of finding Pg DNA in these compartments [16]. Several studies on animal models seem to strengthen the idea of a relationship between Pg and the pathogenesis of RA [17, 18, 19, 20], although possible biases should be taken into account.

To date, given the mainly intracellular life of Pg, there are no data regarding the presence of the bacterium in the synovial tissue of RA patients, nor concerning the possible link with clinical and genetic factors. The aims of the study were a) to see whether Pg DNA could be found in the synovial tissue of RA patients and compare it to patients affected by other arthritides, b) to determine whether the prevalence of DNA positivity in other compartments such as dental plaque and peripheral blood of RA patients could differ from that of patients with other arthritides, and c) to assess the possible links between the presence of Pg DNA and clinical, immunological and genetic features.

## **Methods**

### **Patients: case-control study**

Sixty-nine consecutive patients with active knee arthritis undergoing synovial biopsy from October 2010 till February 2012 at the Division of Rheumatology of the Catholic University of the Sacred Heart of Rome have been included in the study. Twenty-six healthy donors were included in the study, as well. The ethical approval for the study was obtained from the Catholic University of the Sacred Heart Ethical Committee. Informed written consent was obtained from all the patients and healthy donors. The research is in compliance with the

Helsinki Declaration. The following samples were collected for every patient: a) peripheral blood, b) sub-gingival dental plaque as previously described [16], c) synovial fluid through joint aspiration, d) synovial tissue through ultrasound-guided percutaneous needle synovial biopsy (14G Tru-cut Precisa 1410 - Hospital Service). Thirty-two (46.4%) rheumatoid arthritis (RA) patients fulfilling at least six of the ACR/EULAR criteria for RA [21] were considered as case population. The control group consisted of 37 subjects with other arthritides. Moreover, samples of peripheral blood and sub-gingival dental plaque were collected from healthy donors.

### **Laboratory and clinical data**

All patients' sera were tested for the presence of ACPA (Axis-Shield Diagnostics, Dundee, UK), IgM and IgA-rheumatoid factor (RF) autoantibodies (Orgentec diagnostika, Mainz, Germany for IgM and IgA RFs). IgM and IgA RF were considered positive if values were  $\geq 20$  U/ml; ACPA were positive if  $\geq 5$  U/ml. Patients were tested for erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), complete blood count and synovial fluid cell count, as well. Tender and swollen joint count and Ritchie articular index were obtained, as well as pain visual analogue scale, global health status and health assessment questionnaire disability index (HAQ-DI). Disease activity score (DAS) was calculated in order to assess the disease activity of patients with rheumatoid arthritis. The presence of joint erosions was evaluated through conventional hands and feet radiograms. Other clinical variables (e.g. smoking) were obtained through medical history investigation. Actual therapies with conventional and/or biologic disease modifying anti-rheumatic drugs (DMARDs) and/or steroid were recorded.

### **Human leukocyte antigen-DR (HLA-DR) assessment**

DNA was extracted by a blood sample through QuickGene DNA Whole Blood kit (Life Science, Fujifilm Corporation, Tokyo, Japan). The extracted DNA was used for molecular

typing of the HLA-DR haplotype at allele group level, using the Inno-LiPA HLA-DRB1 Amp Plus kit (Innogenetics N.V., 9052 Gent, Belgium), according to manufacturer's instructions.

### **Histological analysis of the synovial tissue**

Histological examination of the synovial tissue samples through direct optical microscopy was performed on 43 of the studied patients (62.3%). The other samples were excluded due to the lack of informativeness. Tissue specimens were fixed with formaldehyde, dehydrated with alcohol, diaphanised with xylol, included in paraffin, sectioned in slices of ~10 µm, applied on a slide and then coloured with haematoxylin-eosin. A Leica DM 2000 optical microscope has been used for the analysis (Leica Microsystems GmbH, Wetzlar, Germany). Bioptic samples were evaluated by two independent assessors. A binary score was used in order to classify the infiltrate patterns as aggregate or diffuse [22].

### ***Porphyromonas gingivalis* DNA detection**

Nucleic acid isolation were performed after resuspension of sub-gingival dental plaque samples and shredding of the synovial tissue specimens; all the samples were incubated for 30' at 37°C with a lysis solution and lysozyme (5 mg/ml), and then for 15' at 56°C with the addition of proteinase K. DNA was extracted using a QIAmpDNA Minikit (Qiagen SpA, Milan, Italy) according to the manufacturer's instructions. The presence of Pg DNA was tested through polymerase chain reaction (PCR). Briefly, oligonucleotides 5'-AGG CAG CTT GCC ATA CTG CG-3' and 5'-ACT GTT AGC AAC TAC CGA TGT-3' were used as primers for a 404 bp amplicon derived from the 16S rRNA, as previously described [23]. Each assay used 5 µl of eluted nucleic acids and 20 pmol of each primer. The reaction mixture contained 25 µl of HotStart Taq Master Mix (Qiagen S.p.A., Milan, Italy) and 10 µl



of RNase-free water in a final volume of 50  $\mu$ l. The amplification profile consisted of 15 min at 95°C to activate the HotStar-Taq DNA polymerase (Qiagen S.p.A., Milan, Italy) followed by 40 cycles at 95°C for 30 sec, 60°C for 45 sec and 72°C for 45 sec. Assays were performed with an iCycler Thermal cycler (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Amplicons were detected by electrophoresis in a 2% agarose gel, visualized by ethidium bromide staining. In each amplification run, distilled water was used as negative control and genomic DNA from ATCC 33277 strain as positive control. Procedures to prevent specimen contamination and PCR carryover were rigorously observed at all stages. To assess sensitivity, specific PCR products were cloned into the pCR2.1 vector (Invitrogen, San Diego, CA, USA) and quantified by O.D. measurement. Constructs were serially diluted and subsequently amplified with Pg-specific primers. PCR for *P. gingivalis* was shown to detect concentrations as low as 5 copies per sample. Randomly selected samples were retested for the presence of *P. gingivalis* DNA using real-time PCR Standard kit (Genesig, Eppendorf, England) according to manufacturer's directions.

### **Statistical analysis**

Data were analyzed using IBM SPSS Statistics 20.0 (IBM Corp., Armonk, NY, USA) and Prism software 5.0 (Graph-Pad, S. Diego, CA 92121-USA).

Categorical and quantitative variables were respectively described as numbers, percentages (%) and mean  $\pm$  standard deviation (SD). Mann-Whitney's test was used to compare continuous variable. Categorical variables were analyzed using  $\chi^2$  test or Fisher's test, depending on sample size restrictions.

The concordance among the PCR and real-time PCR tests results was evaluated by Cohen's kappa statistic, as described by Fleiss [24].

A value of  $p < 0.05$  was considered statistically significant.

## **Results**

### **Patients' clinical and immunological characteristics**

Demographic and clinical data of the 32 patients with RA, 14 with undifferentiated peripheral inflammatory arthritis (UPIA) and 23 with other arthritides included in this study are summarized in Table 1. Four RA patients retired the consent for DNA analysis after having obtained the informed consent.

Cases and controls were comparable for age, sex and smoking status. 9 of the RA patients (28.1%) had an early disease (ERA) with a disease duration lower than 1 year. The patients with other arthritides comprised 12 patients with seronegative spondyloarthropathies (SpA) and 11 patients with other forms of arthritis (i.e. gout, polymyalgia rheumatica, Sjögren syndrome, systemic lupus erythematosus, eosinophilic fasciitis, adult-onset Still's disease, osteoarthritis).

RA patients had a high disease activity and a high disability at the moment of the biopsy (mean DAS  $3.74 \pm 1.17$ , mean HAQ-DI  $1.40 \pm 0.78$ ). Disease activity and disability were higher in RA patients than in patients affected by UPIA ( $p < 0.01$ ). 15 (48.4%) RA patients and 3 (25.0%) UPIA patients were positive for at least one tested autoantibody (ACPA, IgM and IgA RF). The presence of joint erosions was significantly higher in RA patients compared to UPIA (63.3% vs. 25.0%,  $p = 0.01$ ) and to patients affected by other arthritides (22.7%,  $p < 0.01$  vs. RA patients). ERA patients had a lower prevalence of erosions compared to patients with a long-standing disease (LSRA) (22.2% vs. 81.0%,  $p <$

0.01). Groups were comparable for DMARDs and steroid therapy, although RA patients were more frequently receiving biologic therapy (RA vs. other arthritides:  $p < 0.01$ ) (Table 1).

### ***Porphyromonas gingivalis* DNA detection**

The analysis of the healthy donors showed a positivity for Pg DNA in the sub-gingival dental plaque in 7 subjects (26.9%). No positivity arose in the peripheral blood of healthy subjects.

Positive results for Pg DNA in the patients' population are summarized in Table 2 and Additional file 1, Table S1. When considering the global positivity for Pg DNA in all the compartments analyzed, no differences arose among cases and controls.

When considering the single areas analyzed, 59.3% of all the patients studied were positive for Pg DNA in the sub-gingival plaque, 20.9% were positive in the joint compartment, and only one patient (affected by LSRA) was positive in the plasma sample. No significant differences arose among patients and healthy donors.

Pg DNA was more present in whole peripheral blood samples than in plasma samples (11.8% vs. 1.5%,  $p = 0.04$ ).

When considering possible differences among cases and controls, no distinction arose in the positivity for Pg DNA in the sub-gingival plaque, plasma and synovial fluid samples. (Table 2). Nevertheless, when analyzing the synovial tissue, the positivity for Pg DNA was significantly different among the subjects analyzed ( $\chi^2 = 8.05$ ,  $p = 0.02$ ). In particular, patients with RA showed a higher positivity of Pg DNA in the synovial tissue compared to controls (33.3% in RA vs. 5.9% in UPIA + Others,  $p < 0.01$ ) and also when compared to UPIA (0%,  $p = 0.04$  vs. RA patients) or other arthritides (8.7%,  $p < 0.01$  vs. RA patients), whereas the difference was not significant when comparing RA only to SpA patients (16.7% in SpA,  $p = ns$  vs. RA patients). No differences arose among LSRA and ERA patients ( $p =$

ns), though patients with UPIA and ERA showed a trend for a higher positivity for Pg DNA in the sub-gingival plaque than patients with LSRA (75% vs. 47.4%,  $p = 0.1$ ).

These results were replicated using the real-time PCR Standard kit. The concordance between the PCR and the real-time PCR tests results was good (84.8%, Kappa = 0.67,  $p < 0.001$ , 95% CI 0.54 - 0.80).

### **Pg DNA positivity and HLA**

Forty-five of the 46 patients with RA and/or UPIA were genotyped for HLA DR. DNA extraction and typing of one patient with UPIA was unsuccessful after 2 attempts. 20 patients (44.4%) were positive for HLA DRB1\*01 and/or DRB1\*04 (shared epitope - SE). 13 patients (28.9%) were positive for HLA DRB1\*01 and 9 (20%) for HLA DRB1\*04.

When evaluating a possible association between a specific HLA genotype and the positivity for Pg DNA, no relationship arose among HLA-SE and Pg detection in any of the compartments analyzed. However, when considering the single alleles (DRB1\*01 or DRB1\*04), UPIA and RA patients carrying HLA DRB1\*04 allele showed a higher positivity for Pg DNA in the synovial tissue compared to patients negative for the allele (57.1% vs. 16.7%,  $p = 0.04$ ). The association between the presence of HLA DRB1\*04 and the positivity for Pg DNA was confirmed also when considering the whole articular compartment (synovial fluid and synovial tissue) (joint Pg positivity: 55.6% in HLA DRB1\*04 positive patients vs. 17.6% in HLA DRB1\*04 negative patients,  $p = 0.03$ ). The same trend occurred when considering only patients affected by RA (joint Pg DNA positivity: 55.6% in HLA DRB1\*04 positive patients vs. 21.7% in HLA DRB1\*04 negative ones) (Additional file 2, Figure S1).

When considering a possible association between clinical variables, HLA and Pg positivity, UPIA and RA patients who were smokers and/or positive for ACPA

autoantibodies and/or positive for HLA DRB1\*04 allele were more frequently positive for Pg DNA in the synovial tissue, compared to patients who were negative for all these clinical/genetic variables (42.9% vs. 10.5%,  $p = 0.05$ ) (Additional file 3, Table S2).

### **Pg DNA positivity and autoantibodies**

When evaluating patients affected by RA, no significant relationship arose between the presence of Pg DNA and the positivity for the tested autoantibodies (ACPA, IgM and IgA RF). However, RA patients positive for Pg DNA in the synovial fluid showed a trend for a higher positivity for IgM RF, compared to patients negative for Pg DNA (100% vs. 25.0%,  $p = 0.08$ ). No relationship arose between the positivity for Pg DNA in any of the compartments analyzed and the title of autoantibodies in seropositive RA patients.

### **Pg DNA positivity and clinical characteristics**

When analyzing the possible links between Pg DNA and the clinical variables in patients affected by RA, we found that patients positive for Pg DNA in the sub-gingival plaque had a shorter disease duration (Pg positive  $4.2 \pm 5.9$  years vs. Pg negative  $9.3 \pm 8.4$  years,  $p = 0.03$ ), and tended to be more commonly smokers compared to patients negative for Pg in the plaque sample (Pg positivity: smokers 88.9% vs. non-smokers 54.5%,  $p = 0.07$ ). No differences arose regarding the other clinical variables analyzed. In particular, no differences were noted in the activity and disability indexes (DAS and HAQ-DI) among RA patients positive or negative for Pg DNA.

The presence of Pg DNA in the sub-gingival plaque was associated with modifications in the cell blood count: RA patient positive for Pg DNA had a higher leucocytes and neutrophils count compared to patients negative for the bacterium (leucocytes: Pg positive RA  $8.04 \pm 1.82$  cells  $\times 10^9/L$  vs. Pg negative RA  $6.41 \pm 1.05$  cells  $\times 10^9/L$ ,  $p =$

0.02; Neutrophils: Pg positive RA  $5.23 \pm 1.69$  cells  $\times 10^9/L$  vs. Pg negative RA  $3.76 \pm 1.09$  cells  $\times 10^9/L$ ,  $p = 0.03$ ) (Figure 1).

No relationship arose between Pg DNA positivity and synovial fluid cell count.

### **Pg DNA and the histological pattern of the synovial tissue**

13 patients (30.2%) presented an aggregate organization of the synovial tissue, whereas the other 30 (69.8%) had a diffuse infiltrate. An aggregate pattern was more frequent among RA patients (aggregate in RA: 76.9% vs. aggregate in other patients: 23.1%,  $p = 0.04$ ) and was associated with the positivity for ACPA (ACPA positivity: aggregate 61.5% vs. diffuse 14.3%,  $p = 0.004$ ), for IgM RF (IgM RF positivity: aggregate 46.2% vs. diffuse 10.7%,  $p = 0.02$ ) and for IgA RF (IgA RF positivity: aggregate 30.8% vs. diffuse 3.6%,  $p = 0.02$ ). Patients with an aggregate pattern presented a higher neutrophils count in the synovial fluid (SF) than patients with a diffuse infiltrate (SF neutrophils: aggregate  $19.75 \pm 15.18$  cells  $\times 10^9/l$  vs.  $8.06 \pm 9.72$  cells  $\times 10^9/l$ ,  $p = 0.01$ ). An aggregate pattern of the synovial tissue was more frequent among people carriers of HLA shared epitope compared to patients negative for the alleles (50.0% vs. 9.1%,  $p = 0.04$ ).

When evaluating a possible link between a specific structural pattern of the synovial tissue and the positivity for *Porphyromonas gingivalis* DNA, no relationship arose in any of the compartments analysed.

### **Discussion**

In the scientific community it is well accepted that *Porphyromonas gingivalis* (Pg) latent-chronic infection might be one determinant of the citrullination process, because of the

peptidyl-arginine-deiminase activity that could potentially lead to the loss of tolerance to citrullinated peptides, thus leading to the occurrence of anti-citrullinated peptides autoantibodies (ACPA) [11, 13]. Previously it was shown that antibodies against Pg were more frequent in RA (and in periodontitis patients) than in controls [25] and that these antibodies correlated with ACPA. Since a correlation with CRP was also observed the main conclusion was that this organism could play a role in disease risk and progression of RA. The occurrence of periodontal disease in many patients with RA is also well established and there is evidence that Pg bacteria induce inflammatory cytokines and proteases by either mononuclear cells and fibroblasts [26, 27]. Therefore Pg can also contribute to the systemic inflammation.

Here we show that Pg DNA can be found in the sub-gingival plaque and in saliva, rarely yet possibly in the PBMCs and even more rarely in plasma, but more frequently in the joint compartment (in the synovial tissue more than in the synovial fluid). Our data support the possibility that the genetic material was carried out from teeth to joints [28].

The possibility that oral bacteria or their genetic material could reach the joints, was indeed proven by Moen et al. [15]. These Authors found more genetic material in the synovial fluid than in plasma, but they observed no relationship with the parameters of the inflammatory status (no correlation with CRP, white blood cells count, platelets). Therefore the possibility to have a migration from the oral to the joint compartment was hypothesized, though bacteria seemed to have no link with inflammation. Martinez-Martinez et al. [16] confirmed the possibility of a transport of oral genetic material to the joints, since they found among various oral pathogens also Pg more frequently in the synovial fluid than in serum and discussed the possibility of a free DNA transport to the joint compartment.

Our data shed more light on the issue, since we observed that Pg DNA is present similarly in UPIA and RA, it is found in the whole blood (of interest more in UPIA than in RA), more rarely in plasma and in the synovial fluid, but it can be found in the synovial bioptic tissue in one third of RA patients. Although the sample size lacks the power for further assumptions, we also observed that the presence of Pg DNA associates with an increased PBMCs count in the peripheral blood, mostly with PMN cells, thus possibly contributing to the inflammatory status.

We agree with previous papers that no strict relationship exists between the presence of Pg DNA and ACPA or RF levels [29]. Notably, the Pg DNA presence in the oral compartment was mostly observed in early RA patients than in long standing ones, in accordance with the recent findings by J.U. Scher *et al.* [29]. Furthermore, oral Pg DNA was associated with the DR4 epitope. This suggests that the persistence in ERA possibly relies in a defective clearance of Pg by RA patients DR4 carriers. This of course should be tested and verified in vitro and in further cohorts. The well defined immunostimulatory properties of Pg DNA, known to stimulate macrophages and fibroblasts to produce tumor necrosis factor alpha and interleukin-6 in a dose-dependent manner, might explain why its persistence could induce a more inflammatory intra-articular inflammation. These stimulatory effects are due to unmethylated CpG motifs within the bacterial DNA and may represent a continuous and persistent inflammatory loop [30].

## **Conclusions**

Albeit our data cannot support that the presence of *Porphyromonas gingivalis* DNA represents a surrogate marker for the occurrence of ACPA [31], certainly the presence of Pg DNA in UPIA and the presence in the synovial tissue of RA patients, suggests that the



bacterium has a role in the pathogenesis of RA, which can still be maintained long after the initial disruption of the immunologic tolerance.

### **Abbreviations**

ACPA, anti-citrullinated protein antibodies; CRP, C-reactive protein; DAS, disease activity score; DMARDs, disease modifying anti-rheumatic drugs; ERA, early rheumatoid arthritis; ESR, erythrocyte sedimentation rate; HAQ-DI, health assessment questionnaire disability index; HLA, Human leukocyte antigen; LSRA, long-standing rheumatoid arthritis; PAD, peptidyl-arginine-deiminase; PBMCs, peripheral blood mononuclear cells; PCR, polymerase chain reaction; Pg, *Porphyromonas gingivalis*; RA, Rheumatoid arthritis; RF, rheumatoid factor; SD, standard deviation; SpA, seronegative spondyloarthropaties; UPIA, undifferentiated peripheral inflammatory arthritis.

### **Competing interests**

The authors declare that they have no competing interests.

### **Authors' contributions**

MCT performed the experiments, collected patients' data, analysed the data, wrote the manuscript. PC conceived and designed the experiments, performed the experiments, analysed the data, contributed reagents/materials/analysis tools, wrote the manuscript. FR performed the experiments, contributed reagents/materials/analysis tools. BT performed the

experiments, analysed the data. EG collected patients' data. ALF collected patients' data. SD performed the experiments. SM performed the experiments. GDS performed the experiments. SC performed the experiments. GF conceived and designed the experiments, performed the experiments, analysed the data, contributed reagents/materials/analysis tools, wrote the manuscript. All authors have read and approved the final manuscript for publication.

## References

1. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, Silman AJ: **Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins.** *Arthritis Rheum* 2000, **43**:30-37.
2. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E: **Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1 \*0401 MHC class II molecule.** *J Immunol* 2003, **171**:538-541.
3. Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L: **A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis.** *Arthritis Rheum* 2004, **50**:3085-3092.
4. Hill JA, Southwood S, Sette A, Jenikar AM, Bell DA, Cairns E: **The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis associated HLA-DRB1\*0401 MHC class II molecule.** *J Immunol* 2003, **171**:538-541.

5. Oldstone MB: **Molecular mimicry and autoimmune disease.** *Cell* 1987, **50**:819-820.
6. Wilbrink B, van der Heijden IM, Schouls LM, van Embden JD, Hazes JM, Breedveld FC, Tak PP: **Detection of bacterial DNA in joint samples from patients with undifferentiated arthritis and reactive arthritis, using polymerase chain reaction with universal 16S ribosomal RNA primers.** *Arthritis Rheum* 1998, **41**:535-543.
7. Van der Heijden IM, Wilbrink B, Tchetverikov I, Schrijver IA, Schouls LM, Hazenberg MP: **Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides.** *Arthritis Rheum* 2000, **43**:593-598.
8. Lamont RJ, Jenkinson HF: **Life below the gum line: pathogenic mechanisms of *Porphyromonas gingivalis*.** *Microbiol Mol Biol Rev* 1998, **62**:1244-1263.
9. Rosenstein ED, Greenwald RA, Kushner LJ, Weissmann G: **Hypothesis: the humoral immune response to oral bacteria provides a stimulus for the development of rheumatoid arthritis.** *Inflammation* 2004, **28**:311-318.
10. De Smit MJ, Brouwer E, Vissink A, van Winkelhoff AJ: **Rheumatoid arthritis and periodontitis; a possible link via citrullination.** *Anaerobe* 2011, **17**:196-200.
11. Wegner N, Wait R, Sroka A, Eick S, Nguyen KA, Lundberg K, Kinloch A, Culshaw S, Potempa J, Venables PJ: **Peptidylarginine deiminase from *Porphyromonas gingivalis* citrullinates human fibrinogen and  $\alpha$ -enolase: implications for autoimmunity in rheumatoid arthritis.** *Arthritis Rheum* 2010, **62**:2662-2672.

12. Helminen-Pakkala E, Laine V: **The relationship between periodontal findings and articular involvement in a group of subjects suffering from rheumatoid arthritis.** *Proc Finn Dent Soc* 1973, **69**:52-55.
13. Mercado FB, Marshall RI, Bartold PM: **Inter-relationships between rheumatoid arthritis and periodontal disease.** *J Clin Periodontol* 2003, **30**:761-772.
14. Hitchon CA, Chandad F, Ferucci ED, Willemze A, Ioan-Facsinay A, van der Woude D: **Antibodies to *Porphyromonas gingivalis* are associated with anticitrullinated protein antibodies in patients with rheumatoid arthritis and their relatives.** *J Rheumatol* 2010, **37**:1105-1112.
15. Moen K, Brun JG, Valen M, Skartveit L, Eribe EK, Olsen I, Jonsson R: **Synovial inflammation in active rheumatoid arthritis and psoriatic arthritis facilitates trapping of a variety of oral bacterial DNAs.** *Clin Exp Rheumatol* 2006, **24**:656-663.
16. Martinez-Martinez RE, Abud-Mendoza C, Patiño-Marin N, Rizo-Rodríguez JC, Little JW, Loyola-Rodríguez JP: **Detection of periodontal bacterial DNA in serum and synovial fluid in refractory rheumatoid arthritis patients.** *J Clin Periodontol* 2009, **36**:1004-1010.
17. Cantley MD, Haynes DR, Marino V, Bartold PM: **Pre-existing periodontitis exacerbates experimental arthritis in a mouse model.** *J Clin Periodontol* 2011, **38**:532-541.
18. Bartold PM, Marino V, Cantley M, Haynes DR: **Effect of *Porphyromonas gingivalis*-induced inflammation on the development of rheumatoid arthritis.** *J Clin Periodontol* 2010, **37**:405-411.

19. Trombone AP, Claudino M, Colavite P, de Assis GF, Avila-Campos MJ, Silva JS, Campanelli AP, Ibañez OM, De Franco M, Garlet GP: **Periodontitis and arthritis interaction in mice involves a shared hyper-inflammatory genotype and functional immunological interferences.** *Genes Immun* 2010, **11**:479-489.
20. Kinloch AJ, Alzabin S, Brintnell W, Wilson E, Barra L, Wegner N, Bell DA, Cairns E, Venables PJ: **Immunization with *Porphyromonas gingivalis* enolase induces autoimmunity to mammalian  $\alpha$ -enolase and arthritis in DR4-IE-transgenic mice.** *Arthritis Rheum* 2011, **63**:3818-3823.
21. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, et al.: **Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.** *Arthritis Rheum* 2010, **62**:2569-2581.
22. Yanni G, Whelan A, Feighery C, Bresnihan B: **Analysis of cell populations in rheumatoid arthritis synovial tissues.** *Semin Arthritis Rheum* 1992, **21**:393-399.
23. Slots J, Ashimoto A, Flynn MJ, Li G, Chen C: **Detection of putative periodontal pathogens in subgingival specimens by 16S ribosomal DNA amplification with the polymerase chain reaction.** *Clin Infect Dis* 1995, **20**(Suppl 2):304-307.
24. Fleiss JL: *Statistical methods for rates and proportions.* New York: John Wiley & Sons Inc.; 1981.

25. Mikuls TR, Payne JB, Reinhardt RA, Thiele GM, Maziarz E, Cannella AC, Holers VM, Kuhn KA, O'Dell JR: **Antibody responses to *Porphyromonas gingivalis* (*P. gingivalis*) in subjects with rheumatoid arthritis and periodontitis.** *Int Immunopharmacol* 2009, **9**:38-42.
26. Fagundes JA, Monoo LD, Euzébio Alves VT, Pannuti CM, Cortelli SC, Cortelli JR, Holzhausen M: ***Porphyromonas gingivalis* is associated with protease-activated receptor-2 upregulation in chronic periodontitis.** *J Periodontol* 2011, **82**:1596-1601.
27. Belibasakis GN, Bostanci N, Reddi D: **Regulation of protease-activated receptor-2 expression in gingival fibroblasts and Jurkat T cells by *Porphyromonas gingivalis*.** *Cell Biol Int* 2010, **34**:287-292.
28. Loyola-Rodriguez JP, Martinez-Martinez RE, Abud-Mendoza C, Patiño-Marin N, Seymour GJ: **Rheumatoid arthritis and the role of oral bacteria.** *J Oral Microbiol* 2010, **21**:2.
29. Scher JU, Ubeda C, Equinda M, Khanin R, Buischi Y, Viale A, Lipuma L, Attur M, Pillinger MH, Weissmann G, Littman DR, Pamer EG, Bretz WA, Abramson SB: **Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis.** *Arthritis Rheum* 2012, **64**:3083-3094.
30. Nonnenmacher C, Dalpke A, Zimmermann S, Flores-De-Jacoby L, Mutters R, Heeg K: **DNA from periodontopathogenic bacteria is immunostimulatory for mouse and human immune cells.** *Infect Immun* 2003, **71**:850-856.
31. Hitchon CA, El-Gabalawy HS: **Infection and rheumatoid arthritis: still an open question.** *Curr Opin Rheumatol* 2011, **23**:352-357.

**Figure 1. White blood cells count and blood neutrophils count according to the positivity for *Porphyromonas gingivalis* in the sub-gingival plaque in RA patients. WBC: white blood cells; Neut.: neutrophils; PB: peripheral blood; Pg: *Porphyromonas gingivalis*.**

**Table 1. Patients' clinical and immunological characteristics.**

	<i>RA</i>	<i>UPIA</i>	<i>Others</i>	<i>p<sup>a</sup></i>	<i>p<sup>b</sup></i>	<i>p<sup>c</sup></i>
<i>Number</i>	32	14	23	-	-	-
<i>Age, mean ± SD (years)</i>	54.2 ± 17.9	47.8 ± 13.1	47.8 ± 16.7	ns	ns	ns
<i>N. females/males, (% F)</i>	24/8 (75.0)	11/3 (78.6)	14/9 (60.9)	ns	ns	ns
<i>Duration, mean ± SD (years)</i>	6.5 ± 7.5	3.6 ± 5.3	3.8 ± 6.2	ns	ns	ns
<i>ESR, mean ± SD (mm 1<sup>st</sup>h)</i>	62.1 ± 39.2	33.6 ± 26.8	35.9 ± 30.9	<b>0.02</b>	<b>0.01</b>	ns
<i>CRP, mean ± SD (mg/l)</i>	40.7 ± 47.4	15.6 ± 16.9	28.6 ± 49.0	ns	ns	ns
<i>DAS, mean ± SD</i>	3.74 ± 1.17	2.25 ± 0.85		<b>&lt;0.01</b>	-	-
<i>HAQ-DI, mean ± SD</i>	1.40 ± 0.78	0.69 ± 0.91	0.91 ± 0.72	<b>0.01</b>	<b>0.04</b>	ns
<i>ACPA ≥ 5.0 U/ml (%)</i>	13 (40.6)	1 (7.7)	1 (4.5)	<b>&lt;0.01</b>	<b>&lt;0.01</b>	ns
<i>IgM RF ≥ 20.0 U/ml (%)</i>	9 (28.1)	2 (15.4)	1 (4.5)	ns	<b>0.05</b>	ns
<i>IgA RF ≥ 20.0 U/ml (%)</i>	6 (18.8)	1 (7.7)	0	ns	ns	ns
<i>DMARDs therapy, n. (%)</i>	27 (84.4)	8 (57.1)	19 (82.6)	ns	ns	ns
<i>Biologic therapy, n. (%)</i>	10 (31.3)	0	2 (8.7)	<b>0.02</b>	<b>0.05</b>	ns
<i>Steroid therapy, n. (%)</i>	22 (68.8)	6 (42.9)	12 (52.2)	ns	ns	ns

RA = rheumatoid arthritis; UPIA = undifferentiated peripheral inflammatory arthritis; Others = other arthritides; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; DAS = disease activity score; HAQ-DI = health assessment questionnaire disability index; GH = global health; VAS = visual analogue scale; SD = standard deviation; ns = not significant. a= RA vs. UPIA, b = RA vs. Others, c = UPIA vs. Others.



**Table 2. Positive results for *Porphyromonas gingivalis* DNA.**

	<i>RA</i>	<i>UPIA</i>	<i>Others</i>
<i>Total</i>	22/31 (71.0)	11/14 (78.6)	16/21 (76.2)
<i>Plasma</i>	1/31 (3.2)	0/14	0/21
<i>Full peripheral blood</i>	2/21 (9.5)	3/12 (25.0)	1/18 (5.6)
<i>Synovial fluid</i>	2/30 (6.7)	1/12 (8.3)	1/20 (5.0)
<i>Synovial tissue</i>	9/27 (33.3)	0/11	2/23 (8.7)
<i>Plaque</i>	14/26 (53.8)	10/13 (76.9)	11/21 (52.4)

All the values are considered as number of positives / total number (%). RA = rheumatoid arthritis; UPIA = undifferentiated peripheral inflammatory arthritis; Others = other arthritides.

## **Additional files**

**Additional file 1. Table S1.** Patients list with demographic, genetic and immunologic data and positivity for *Porphyromonas gingivalis*.

**Additional file 2. Figure S1.** Positivity for *Porphyromonas gingivalis* DNA in the synovial tissue and HLA alleles.

**Additional file 3. Table S2.** Positivity for *Porphyromonas gingivalis* DNA in the synovial tissue, ACPA positivity, smoking status and HLA DRB1\*04 allele.





Figure 1

**Additional files provided with this submission:**

Additional file 1: Additional file 1, Table S1.xls, 37K

<http://arthritis-research.com/imedia/2107183260970946/supp1.xls>

Additional file 2: Additional file 2, Figure S1.doc, 53K

<http://arthritis-research.com/imedia/1900055416970946/supp2.doc>

Additional file 3: Additional file 3, Table S2.xls, 20K

<http://arthritis-research.com/imedia/1998065241970919/supp3.xls>